<DOC>
	<DOCNO>NCT02765373</DOCNO>
	<brief_summary>This study prospective , controlled phase IV clinical trial among postmenopausal patient hormone receptor-positive breast cancer.The main purpose compare effect steroidal aromatase inhibitor ( AI ) exemestane non-steroidal AIs lipid level breast cancer patient .</brief_summary>
	<brief_title>Effects Adjuvant Endocrine Therapy With Aromatase Inhibitors Postoperative Lipid Levels Postmenopausal Breast Cancer Patients</brief_title>
	<detailed_description>The study subject compose postmenopausal woman hormone receptor-positive breast cancer receive exemestane , anastrozole letrozole follow test safety variable low-density lipoprotein- cholesterol ( LDL-C ) , triglyceride ( TC ) , total cholesterol , high-density lipoprotein cholesterol ( HDL ) , blood calcium , transaminase fast plasma glucose different time interval two year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Pathologic analysis verifies earlystage invasive breast cancer immunohistochemistry show estrogen receptor ( ER ) and/or progesterone receptor ( PR ) positive ( ER/PR positive define &gt; 1 % cell positive ) . 2 . The patient receive surgery breast cancer recover well interval least 1 week . 3 . The patient receive postoperational adjuvant chemotherapy and/or adjuvant radiotherapy whereas interval chemotherapy and/or adjuvant radiotherapy 2 week . 4 . The postmenopausal woman confirm menopausal define NCCN guideline ( include post bilateral oophorectomy ; age≥60 yearold ; age≤60 yearold , menopause 1 year plasma FollicleStimulating Hormone ( FSH ) estradiol level meet menopausal scope ) . 5 . Do receive concomitant endocrine therapy , e.g . druginduced menopause , tamoxifen . 6 . The patient severe cardiopulmonary dysfunction . 7 . ECOG score : 01 8 . The patient enough organ function meet scope aromatase inhibitor ( AIs ) therapy . The laboratory test index must comply follow requirement : Blood routine : neutrophil≥1.5G/L , platelet count ≥75G/L , hemoglobin ≥100g/L Liver function : serum bilirubin ≤ 2 time upper limit normal value ; ALT AST≤3 time upper limit normal value ; Renal function : serumcreatinine≤140μmol/L 9 . Serum low density lipoproteincholesterol ( LDLC ) value &lt; 3.37mmol/L 10 . Imaging examination identifies none local recurrence distal metastasis . 11 . No combined malignancy . 12 . The patient good compliance therapy followup schedule able understand study protocol sign Informed Consent Form . Exclusion criteria 1 . The patient qualify receive adjuvant endocrine therapy AIs . 2 . The patient previously receive endocrine therapy ( e.g . tamoxifen ) simultaneity treatment AIs ( exclude course le 3 month ) 3 . The patient receive receive lipidlowering therapy . 4 . The patient suffer combined malignancy . 5 . The patient uncontrollable mental illness . 6 . The patient experience severe cardiovascular disease recent 6 month ( e.g . unstable angina , chronic heart failure , uncontrollable hypertension &gt; 150/90 mmHg , myocardial infarction cerebrovascular disorder ) .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>aromatase inhibitor</keyword>
	<keyword>lipid level</keyword>
</DOC>